About
News
Calendar
Education & Training
Careers
How to Help
Contact Us
My Dana-Farber
Español
Find a Doctor
Get Directions
For Physicians
Make a Gift
Adult Care
Treatment and Care
Treatment Centers and Clinical Services
Care Team
Patient And Family Support
Care Quality and Patient Safety
Patient Stories
For Adult Cancer Survivors
Browse by Cancer Type
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
New Patient Guide
Planning a Visit
Driving Directions
Parking at Dana-Farber
Maps of Dana-Farber
Preparing for Your First Visit
How to Prepare
Talking to Your Doctor
Financial and Legal Matters
Insurance and Financial Assistance
Your Role as Patient
Ethics Consultation
Health Care Proxy
Special Assistance
Interpreters
Patient Navigators
Disability Services
Patient Safety and Advocacy
Safety Information
Patient Relations
Adult Patient and Family Advisory Council
Legislative Action Network
Amenities and Resources
Concierge Services
Appointments & Second Opinions
New Patient?
For appointments or second opinions:
Adults:
(877) 442-DFCI (442-3324)
Children:
(888) PEDI-ONC (733-4662)
or complete the
Appointment Request Form
Online Specialty Consultations
International Patients
Referring Physician?
To refer an adult patient:
(877) 441-DFCI (441-3324)
To refer a pediatric patient:
(888) PEDI-ONC (733-4662)
or complete the
Patient Referral Form
Pediatric Care
Treatment and Care
Pediatric Treatment Centers and Clinical Services
Care Team
Patient And Family Support
Care Quality and Patient Safety
Patient Stories
For Survivors of Childhood Cancer
Browse by Cancer Type
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
New Patient Guide
Planning a Visit
Driving Directions
Parking at Dana-Farber
Maps of Dana-Farber
Preparing for Your First Visit
How to Prepare
Talking to Your Child's Doctor
Financial and Legal Matters
Insurance and Financial Assistance
Your Role as Patient
Ethics Consultation
Health Care Proxy
Special Assistance
Interpreters
Disability Services
Patient Safety and Advocacy
Safety Information
Patient Relations
Legislative Action Network
Pediatric Patient and Family Advisory Council
Amenities and Resources
Concierge Services
Appointments & Second Opinions
New Patient?
For appointments or second opinions:
Adults:
(877) 442-DFCI (442-3324)
Children:
(888) PEDI-ONC (733-4662)
or complete the
Appointment Request Form
Your Child's Care Team
For International Patients
Referring Physician?
To refer an adult patient:
(877) 441-DFCI (441-3324)
To refer a pediatric patient:
(888) PEDI-ONC (733-4662)
or complete the
Patient Referral Form
Research
Clinical Trials
Research Advances
Featured Research
Departments and Centers
Integrative Research Centers
Core Facilities
Research Administration
Technology Transfer
Find a Researcher
Health Library
Blog
Home
Research
Clinical Trials
Clinical Trials by Diagnosis
Melanoma Clinical Trials
Showing 1-5 of 5 items
1.
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
The purpose of this study is to evaluate how effective SU011248 works in treating acral lentiginous and mucosal melanoma which has spread beyond the local region. SU011248 is a protein-tyrosine kinase inhibitor and acts as a c-kit inhibitor drug. It is believed to work by blocking signals on certain cancer cells which allow the malignant cells to multiply and spread due to a change in the genetic make up of the cancer cell.
Diagnoses:
Melanoma
Status:
Recruiting
2.
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with locally advanced or metastatic mucosal melanoma or acral melanoma.
Diagnoses:
Melanoma
Status:
Recruiting
3.
STA-9090(Ganetespib) in Metastatic Ocular Melanoma
STA-9090 is drug which inactivates or blocks the work of a protein called Heat Shock Protein 90 or HSP90. HSP90 is a protein that helps some molecules inside the cells have the right shape. By stopping it's activity, these molecules never get to have the right structure to be functional and they are destroyed. We believe that if we stop the activity of HSP90, the rapidly dividing cells in the tumor(s) will slow down since their proteins will not be functional without the help of HSP90.
Diagnoses:
Melanoma
Status:
Recruiting
4.
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212
This is an open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2118436 and GSK1120212 in combination. This study is designed in three parts. In Part A, the effect of repeat doses of GSK1120212 on the pharmacokinetics of single dose GSK2118436, will be investigated prior to evaluating combination regimens. In Part B, the range of tolerated dose-combinations will be identified using a dose-escalation procedure. In Part C, different dose combinations of GSK2118436 and GSK1120212 will be evaluated, based on results from the dose escalation cohorts.
Diagnoses:
Melanoma
Status:
Recruiting
5.
A Study of MPDL3280A in Combination With Avastin (Bevacizumab) or With Avastin Plus Chemotherapy in Patients With Advanced Solid Tumors
The primary aim of the study is to assess the safety, pharmacology and preliminary efficacy of MPDL3280A [a monoclonal antibody that targets programmed cell death-1 ligand 1 (PD-L1)] administered with bevacizumab (Arm A) and with bevacizumab plus chemotherapy (Arm B) in patients with advanced solid tumors.
Diagnoses:
Melanoma
Status:
Recruiting
Showing 1-5 of 5 items
Email
Print
Share
Text
Highlight Glossary Terms